Ovarian Cancer

Featured

News
Cost-Sharing Patterns for PARP Inhibitor Therapy in Ovarian Cancer
Results from a single-center study show payers incur the bulk of monthly PARP inhibitor cost for ovarian cancer.
News
Targeted Genetic Testing Cost-Effective for Breast and Ovarian Cancer
Targeted BRCA or multiple gene screening is cost-effective for preventing breast and ovarian cancer, according to a…
Quiz
Quiz: Rucaparib vs Chemotherapy for BRCA-Mutated Ovarian Cancer
True or False: Rucaparib improves PFS compared with chemotherapy in patients with relapsed BRCA-mutated ovarian cancer.
News
Total and Out-of-Pocket Costs of PARP Inhibitor Therapy for Ovarian Cancer
PARP inhibitor therapy costs account for over 90% of patients’ total out-of-pocket drug spending. However, payers are…
News
Emerging Immunotherapy Targets in Gynecologic Cancer
A recent article summarized the characteristics and preclinical/clinical progress of emerging immunotherapy targets in…

News

Cost-Sharing Patterns for PARP Inhibitor Therapy in Ovarian Cancer
Targeted Genetic Testing Cost-Effective for Breast and Ovarian Cancer
Total and Out-of-Pocket Costs of PARP Inhibitor Therapy for Ovarian Cancer
Cost-Effectiveness of Genomic Screening for Hereditary Breast and Ovarian Cancer

Guideline Updates

NCCN Releases Updated Treatment Guideline for Ovarian Cancer

Interviews

PARP Inhibitors in Front-Line and Maintenance Therapy of Ovarian Cancer: A Changing Standard of Care

Videos

PROs Comparable Between Niraparib, Placebo in Advanced Ovarian Cancer

Podcast

Ovarian Cancer Maintenance: PRIMA, PAOLA-1, VELIA, and Others

Conference Coverage

Olaparib Maintenance Demonstrates Long-Term PFS Benefit for Advanced Ovarian Cancer